Gene Logic to Help H. Lundbeck Reposition, Develop Shelved Drug Candidates | GenomeWeb
NEW YORK (GenomeWeb News) — Gene Logic yesterday said it will help H. Lundbeck reposition and develop certain drugs candidates that were “discontinued” or “de-prioritized” for reasons other than safety.
 
Gene Logic said the deal allows for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck's contribution as the originator of the compound.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.